HS-10541 for advanced solid tumors with KRAS G12C mutation
Part of Cancer clinical trials.
This trial tests a new drug called HS-10541, which may target a specific genetic change in your tumor (KRAS G12C mutation). The study aims to see if this drug is safe and effective, either alone or with other cancer treatments, for people with advanced cancer that hasn't responded to standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has the KRAS G12C mutation (your doctor can check this).
- You have at least one measurable tumor (a tumor that can be seen on scans and measured).
- You are able to take care of yourself (ECOG score 0-1) and have a life expectancy of more than 12 weeks.
- Your blood counts and organ functions (like liver and kidneys) are adequate, and you have no serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral pill called HS-10529 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This study tests a new combination of two oral drugs (GH21 and D-1553) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective in shrinking or controlling the cancer.
Hear when a new KRAS G12C Mutation Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.